Eli Lilly and Company (NYSE:LLY) Shares Sold by National Bank of Canada FI

National Bank of Canada FI lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 13.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 335,670 shares of the company’s stock after selling 50,059 shares during the period. National Bank of Canada FI’s holdings in Eli Lilly and Company were worth $198,855,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the third quarter worth approximately $27,000. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter valued at $35,000. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $36,000. Finally, Family CFO Inc bought a new stake in shares of Eli Lilly and Company during the 3rd quarter worth $40,000. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent analyst reports. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Barclays increased their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $20.94 during trading on Friday, reaching $734.97. The company had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The firm’s 50 day simple moving average is $761.06 and its two-hundred day simple moving average is $671.38. Eli Lilly and Company has a one year low of $419.80 and a one year high of $800.78. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. The company has a market capitalization of $698.52 billion, a PE ratio of 108.24, a PEG ratio of 1.50 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.62 earnings per share. Sell-side analysts forecast that Eli Lilly and Company will post 13.83 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.